Epidemiology of Psoriatic Arthritis

V. Chandran

Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?

S. Pamidi, S. Mehta

Statistics and the Relationship of Clinical Research to Clinical Practice

S.A. Khuder, B. Kahaleh

An Elephant Among Us: The Role of Depression in the Pathophysiology of Fibromyalgia

P.B. Wood, A.J. Holman

Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort

T.L. Rivera, H.M. Belmont, S. Malani, et al.

Dendritic Cells Contribute to Autoimmune Kidney Injury in MRL-Fas(−/−) Mice

Y. Iwata, K. Furuchi, N. Sakai, et al.

Apolipoprotein H Promoter Polymorphisms in Relation to Lupus and Lupus-related Phenotypes


Shifting Our Thinking About Uncommon Disease Trials: The Case of MTX in Scleroderma

S.R. Johnson, B.M. Feldman, J.E. Pope, G.A. Tomlinson

Limitations to the 6-Minute Walk Test in ILD and PHT in Scleroderma

M.C. Garin, K.B. Highland, R.M. Silver, C. Strange

ACE Gene Does Not Contribute to Genetic Susceptibility to SSc in European Caucasians

J. Wipft, G. Gallier, P. Dieude, et al.

CRP Gene Polymorphisms in Biopsy-proven GCA from Northwestern Spain


Association of Fcγ Receptor Polymorphisms with AOSD in Korea


Fertility and Reproduction in Male Patients with AS Treated with Infliximab S. Paschou, P.V. Voulgari, I.G. Vrabie, I.G. Saougu, A.A. Drosos

Pulmonary Tuberculosis and Disease-Related Pulmonary Apical Fibrosis in AS

H.-H. Ho, M.-C. Lin, K.-H. Yu, C.-M. Wang, Y.-J.J. Wu

Time Trends in Epidemiology and Characteristics of PsA Over 3 Decades: A Population-based Study

F.C. Wilson, M. Icen, C.S. Crowson, M.T. McEvoy, S.E. Gabriel, H. Maradit Kremers

Sensitivity of the Classification of PsA Criteria in Early PsA


Is Diabetes Associated with Shoulder Pain or Stiffness?

Results from a Population Based Study


Serum Uric Acid Is Associated with Carotid Plaques:

The NHLBI Family Heart Study

Effectiveness of Specific Neck Stabilization Exercises or a General Neck Exercise Program for Chronic Neck Disorders: A Randomized Controlled Trial
C. Griffiths, K. Dziedzic, J. Waterfield, J. Sim .......................... 390

The Efficacy and Safety of Milnacipran for Treatment of FM: A Randomized, Double-blind, Placebo-controlled Trial
P.J. Mease, D.J. Clauw, R.M. Gendreau, et al. ....................... 398

Pediatric Rheumatology
Access to Pediatric Rheumatology Subspecialty Care in British Columbia, Canada
N.J. Shiff, R. Abdwani, D.A. Cabral, et al. ................................. 410

Autoantibodies in Pediatric SLE: Ethnic Grouping, Cluster Analysis, and Clinical Correlations

Persistent Elevation of Fibrin D-Dimer Predicts Longterm Outcome in Systemic JIA
B.J. Bloom, A.J. Alario, L.C. Miller ........................................ 422

Epidemiologic Considerations in Unexplained Pediatric Arthralgia: The Role of Season, School, and Stress
J.D. McNally, L.A. Matheson, A.M. Rosenberg ......................... 427

Images in Rheumatology
A Black Hole in a Bone — Intracaseous Lipoma
P. Mandl, A. Mester, P.V. Balint ........................................... 434

Marked Regression of Pulmonary Rheumatoid Nodules Under Etanercept Therapy
G. Derot, A. Marini-Portugal, B. Maitre, P. Claudepierre .................... 437

Restrictive Cardiomyopathy Secondary to HCQ Therapy
V.A. Manohar, K.G. Moder, W.D. Edwards, K.W. Klarich .................... 440

Correspondence
Measures of RA Disease Activity
J. Kirwan .................. 442

Reply T. Neogi, D.T. Felson .................. 443

Reply T. Pincus .................. 443

Pulmonary Abnormalities in Patients with Early and Long-standing RA
A.N. Georgiadis, Z.M. Metafratzi, A.A. Drosos .................................. 444

Reply S. Mori, I. Cho ............................................. 445

Anakinra and Its Rapidly Expanding Role in Management of Nonarthritis Systemic Disorders
S. Kapoor .......................... 446

Reply T. Lequerre, O. Vittecoq, X. Le Loët .......................... 447

Do Immunosuppressives Upregulate Antiphospholid Antibodies?
C. Korkmaz .......................... 447

Reply P.G. Vlachoyiannopoulos .......................... 448

Graves’ Disease, RA, and Anti-TNF-α Therapy
J.I. Shin, M.J. Kim, J.S. Lee ........................................... 449

Reply A.W.T. van Lieshout, M.C.W. Creemers,

Bisphosphonate Related Osteonecrosis of the Jaws
E. Fung .......................... 450

Letter G. Campisi, S. Fedele, G. Colella, A. Lo Castro, V. Fusco .................. 451

Reply A. Khan .......................... 453

Destructive TMJ Disease: Also Consider Tophaceous Voracious (Hydroxy)Apatite
M.H. Werner .......................... 453

Reply J.L. Reynolds, I.R. Matthew, A. Chalmers .......................... 454

How Are We Doing in Reviewing Those New Patients Who Need to Be Seen as Early as Possible? An Audit of 264 Consecutive New Patients Seen Over 6 Months in a University Hospital in Ireland
M. Haroon, U. Bond, M. Phelan, M. Regan .......................... 454

Reply A.E. Thompson, S.L. Graydon .......................... 455

Hotel-Based Rheumatology, and More
B.F. Leeb .......................... 456

Letter R. Greenwald .......................... 456

Reply T. Pincus, Y. Yazici, M.J. Bergman .......................... 456

Letters
GCA Revealed by Vertebrobasilar Insufficiency
S. Richard, R. Anxionnat, C. Delaunay, X. Ducrocq .......................... 457

Blockade of IL-6 Signaling Induces Marked Neutropenia in Patients with RA
I. Shin, M.J. Kim, J.S. Lee .......................... 458

Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with MMF
A. Gulamhusein, J.E. Pope .......................... 459

Disseminated Cryptococcal Infection and Anti-TNF-α Treatment for Refractory Sarcoidosis: An Expected Association?
L. Arnaud, D. Sene, N. Costedoat-Chalumeau, P. Cacoub, C. Chapelon-Abric, J-C. Piette .......................... 462

Don’t Judge a Book by Its Cover
A.J. Holman .......................... 463

Book Review
Worried Sick. A Prescription for Health in an Overtreated America .......................... 463

Meetings in Rheumatology .......................... x